Lv6
2720 积分 2021-06-21 加入
Abstract PS1-10-08: Er riptacs drive tumor selective cell death in post-cdk4/6i resistance settings and demonstrate oral efficacy in cdx and pdx models
18天前
已完结
Role of BET proteins in castration-resistant prostate cancer
24天前
已完结
Next-generation strategies for PROTAC formulation: mechanistic insights and advanced formulation technologies
1个月前
已关闭
Navigating the clinical progress of antibody-drug conjugates: Emerging opportunities and remaining challenges
1个月前
已完结
Discovery of a Novel Bromodomain and Extra Terminal Domain (BET) Protein Inhibitor, I-BET282E, Suitable for Clinical Progression
2个月前
已完结
Template-Hopping Approach Leads to Potent, Selective, and Highly Soluble Bromo and Extraterminal Domain (BET) Second Bromodomain (BD2) Inhibitors
2个月前
已完结
Discovery of Novel CBP/p300 and BRD4 Dual-Target PROTACs with Potent Antitumor Activity in Prostate Cancer
3个月前
已完结
Discovery of Cdc20/Hsp90 Dual-Target Inhibitors with Potent Antitumor Activity for Therapy of Acquired Resistant Melanoma
3个月前
已完结
Targeted degradation of BRD4 by PROTACs: advances in cancer therapy
3个月前
已完结
Molecular glue-based RAS–MAPK targeting
3个月前
已完结
皖公网安备34019202002308
